Immunic(NASDAQ) IMUX

Immunic, Inc. makes pills for brain and immune diseases. Its products help patients with multiple sclerosis manage their health. The company turns complex treatments into easy-to-take oral medicine.

Developing New Oral Therapies

• Vidofludimus calcium (IMU-838): Lead treatment candidate in late-stage testing for patients with relapsing multiple sclerosis; focuses on protecting nerve cells and reducing inflammation.
• IMU-856: Oral molecule designed to help restore the intestinal barrier for patients with gut diseases like celiac disease or inflammatory bowel disease.
• IMU-381: Preclinical drug program using a specialized chemical platform to target various neurologic and autoimmune conditions.
• Gliomic Therapeutics: Research division focusing on using chemical compounds to treat brain cancers by blocking specific enzymes.

Recent Strategic Milestones

• February 2026: Secured $187.3 million in net proceeds through a private placement to fund late-stage clinical operations.
• June 2025: Completed enrollment for two Phase 3 trials involving 2,221 patients across 15 countries to test its lead drug for relapsing multiple sclerosis.
• February 2026: Created a 5% royalty interest on future sales of its lead drug in exchange for cancelling certain warrants to streamline its capital.
• March 2026: Granted a European patent for specific drug dosing regimens that provides market protection potentially through 2043.
• June 2026: Appointed Erik Lundgren as chief executive officer to lead the company through its next stage of drug development.

How Immunic Stands Out

Immunic operates a specialized research infrastructure in Germany to manage its drug development programs cost-effectively. The company uses a unique dual-action approach that combines anti-inflammatory effects with neuroprotection to address complex diseases of the nervous system.

Key Financial Results

• Cash and cash equivalents were $155.1 million as of June 30, 2026.
• Net loss was $66.7 million for the six-month period ended June 30, 2026, up 28% year over year.
• Research and development expenses increased 20% to $51.6 million for the six-month period ended June 30, 2026.
• Accumulated deficit reached $675.3 million as of June 30, 2026, reflecting the high costs of drug discovery and clinical testing.
• General and administrative expenses rose 55% to $17 million for the six-month period ended June 30, 2026.

The Long-Term Path

Immunic has transitioned from early research into late-stage clinical trials while securing the funding and leadership needed for potential commercialization. The company remains focused on advancing its neurologic pipeline and protecting its intellectual property in major global markets.